	US 12,257,291 B2
	Human alpha-galactosidase variants
Nicholas J. Agard, San Francisco, CA (US); Mathew G. Miller, San Carlos, CA (US); Xiyun Zhang, Fremont, CA (US); and Gjalt W. Huisman, Redwood City, CA (US)
Assigned to Crosswalk Therapeutics, Inc., Cambridge, MA (US)
Filed by Crosswalk Therapeutics, Inc., Cambridge, MA (US)
Filed on May 6, 2024, as Appl. No. 18/656,340.
Application 18/656,340 is a continuation of application No. 17/196,858, filed on Mar. 9, 2021.
Application 17/196,858 is a continuation of application No. 16/985,742, filed on Aug. 5, 2020, granted, now 10,973,888, issued on Apr. 13, 2021.
Application 16/985,742 is a continuation of application No. 15/529,383, abandoned, previously published as PCT/US2015/063329, filed on Dec. 2, 2015.
Claims priority of provisional application 62/216,452, filed on Sep. 10, 2015.
Claims priority of provisional application 62/095,313, filed on Dec. 22, 2014.
Prior Publication US 2025/0041388 A1, Feb. 6, 2025
Int. Cl. A61K 38/47 (2006.01); A61K 9/00 (2006.01); C12N 9/00 (2006.01); C12N 9/24 (2006.01); C12N 9/40 (2006.01)

CPC A61K 38/47 (2013.01) [A61K 9/0019 (2013.01); C12N 9/2465 (2013.01); C12Y 302/01022 (2013.01)]

19 Claims

1. A recombinant alpha-galactosidase A comprising a polypeptide sequence comprising at least 90% sequence identity to SEQ ID NO: 46, wherein the polypeptide sequence comprises mutations at 316D, 10P, 39E, 44R, 47T, 92H 166P, 206A, 217R, 247D, 261G, 271A, 302K, 3221, 337P, 368A, and 392T.